Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
February 16, 2021 16:45 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market
February 01, 2021 17:16 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Reports Third Quarter 2020 Financial Results
November 12, 2020 16:25 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...
Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering
October 28, 2020 17:54 ET
|
Cancer Genetics, Inc.
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology services,...
Cancer Genetics and StemoniX Announce Joint Proof-of-Concept Program
September 03, 2020 08:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., and MAPLE GROVE, MN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and...
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
June 24, 2020 17:30 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
June 01, 2020 08:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial...
Cancer Genetics Issues Letter to Shareholders
February 20, 2020 09:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and immuno-oncology...
Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update
November 20, 2019 08:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic,...